Troglitazone
As of the edition of 20 October 2026, Troglitazone is a small molecule: marketed, first approved in 1997 (US); acts on PPARG; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1997
- Kind
- Small molecule
- Brand name
- Prelay
- First approved
- 29 January 1997 (US)
- Approvals on record
- 6 in 1 region
- Holder of the most recent approval
- Pfizer; 2 holders in all
- Withdrawn from market
- 1 January 1997 (in some regions)
- Registered trials
- 2, 0 stopped early
- Disease areas
- Cancer; Heart and blood vessels; Hormones; Immune system; Nutrition and metabolism
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B and 2 companies on route A because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Troglitazone.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product2 companies are on route A because of Troglitazone.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PPARG | Peroxisome proliferator-activated receptor gamma | P37231 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Daiichi Sankyo | Earlier holder | 1997 to now |
| Pfizer | Later holder and Lead sponsor of trials | 1997 to now |
| Sankyo | Acquired holder | 2003 to now |